Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01226316
Title Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

Therapies

Capivasertib

Age Groups: adult senior

Additional content available in CKB BOOST